Conference Coverage

Postmenopausal women who shed pounds see lower breast cancer risk


 

REPORTING FROM SABCS 2017

– Postmenopausal women may be able to lower their risk of invasive breast cancer by simply losing some weight, according to an analysis of the large prospective Women’s Health Initiative Observational Study.

“While obesity is an established risk factor for postmenopausal breast cancer, studies of weight loss and breast cancer provide inconsistent results. It’s been very, very difficult to show that losing weight changes breast cancer incidence,” said lead investigator Rowan T. Chlebowski, MD, PhD, research professor in the department of medical oncology and therapeutics research at City of Hope in Duarte, Calif. “Consequently, the current public health message is limited to ‘avoid body fatness’ [N Engl J Med. 2016;375:794-8]. That’s not a very strong public health message.”

Dr. Rowan T. Chlebowski, research professor in the department of medical oncology and therapeutics research at City of Hope in Duarte, Calif. Susan London/Frontline Medical News

Dr. Rowan T. Chlebowski

He and his coinvestigators assessed changes in study participants’ weight during the first 3 years and then ascertained their invasive breast cancer risk after a median follow-up of 11.4 years.

Results showed that compared with peers whose weight remained stable, women who lost at least 5% of their body weight (an average of about 17-20 pounds) had a significant 12% reduction in breast cancer risk, Dr. Chlebowski reported in a session and press briefing at the San Antonio Breast Cancer Symposium. Benefit was similar whether the weight loss was intentional or not, and whether women were normal weight, overweight, or obese at baseline.

“These findings suggest that interventions in postmenopausal women designed to generate weight loss may reduce breast cancer risk. I feel these are very optimistic findings in that they provide a lesson to postmenopausal women that even a moderate degree of weight loss may be associated with health benefits,” he said. “This is a relatively new finding, and I think it should have public health implications.”

Parsing the findings

“I hope that you can present this to general doctors rather than oncologists because those are the ones seeing healthy women, by and large,” said press briefing moderator C. Kent Osborne, MD, codirector of SABCS and director of the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston. “But in my patients, I’ve always suggested that they lose weight. Most of them with breast cancer are overweight, it seems. And I always had to do it because of diabetes and other factors. Now we can do it because we have a breast cancer endpoint that also suggests that losing weight will help with that as well.”

Dr. C. Kent Osborne, codirector of SABCS and director of the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston. Susan London/Frontline Medical News

Dr. C. Kent Osborne

In discussions among the investigators about implementing the study’s findings via weight loss counseling and intervention, reimbursement was identified as an ongoing concern, Dr. Chlebowski noted. “Certainly, oncologists do not get any money for encouraging this or taking any steps to implement this. So that’s another battle that needs to be conducted.”

Additional results from the study showed that women who experienced a weight gain of at least 5% did not have a significantly elevated risk of breast cancer overall.

“Do you think that the women who gained a little bit of weight didn’t have an increase in incidence because they were already overweight?” Dr. Osborne asked.

“When we go over all these very complex mechanisms and the different drivers, there’s probably a threshold. So obesity’s association with inflammatory factors, I think that’s a driver to a certain degree. But then something else takes over, or maybe the main driver takes over,” Dr. Chlebowski replied. “We don’t have enough data to decide exactly what that threshold is, but that’s the ongoing hypothesis.”

In the session, attendee Daniel McGrail, PhD, of the MD Anderson Cancer Center, Houston, asked, “Since this [risk reduction with weight loss] occurred regardless of initial [body mass index], and you have all these covariates accounted for, does that imply that actually caloric deficits or decreasing caloric intake could be preventing breast cancer risk regardless of initial weight or any other parameters?”

“In all these western diseases, what we take for normal is probably less normal than it might have been 250 years ago or thousands of years ago when we were eating berries and being chased by animals,” Dr. Chlebowski replied. “So this raises a question as to whether the normal weight cutoff should be an ideal weight for western cancer prevention.”

Study details

The Women’s Health Initiative Observational Study recruited 93,676 postmenopausal women aged 50-79 years from 40 U.S. clinical centers during 1993-1998. The women had measurements taken of height and weight at baseline and at year 3 for calculation of BMI, and were asked about intentionality of any weight loss during that period.

Pages

Recommended Reading

Ovarian suppression during breast cancer chemo helps stave off early menopause, preserve fertility
MDedge Hematology and Oncology
VIDEO: Novel PARP inhibitor boosts PFS in HER2– breast cancer with BRCA mutations
MDedge Hematology and Oncology
VIDEO: CTCs may identify asymptomatic late breast cancer recurrences
MDedge Hematology and Oncology
Extra years of adjuvant bisphosphonate not needed in early breast cancer
MDedge Hematology and Oncology
Novel PARP inhibitor boosts PFS in HER2- breast cancer with BRCA mutations
MDedge Hematology and Oncology
PANACEA: pembrolizumab overcomes trastuzumab resistance for some
MDedge Hematology and Oncology
CDK4/6 inhibitors have similar efficacy in older breast cancer patients
MDedge Hematology and Oncology
VIDEO: SABCS 2017 roundtable with Dr. Hope S. Rugo and Dr. William J. Gradishar
MDedge Hematology and Oncology
High rate of arm morbidity in young breast cancer survivors
MDedge Hematology and Oncology
Hallmark tumor metabolism becomes a validated therapeutic target
MDedge Hematology and Oncology